and nivolumab after the radiation. After clinical deterioration within 4 weeks of starting checkpoint therapy, the patient showed a marked increase in T2 changes outside the radiation field.

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. It can affect arteries, veins, and capillaries. This condition causes blood vessel walls to swell, which ...

Introduction: Primary central nervous system vasculitis (PCNSV) is a rare inflammatory arteriopathy confined to the brain, spinal cord, and leptomeninges. Because of its nonspecific presentation ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared with sunitinib in patients with advanced RCC. The combination therapy showed a median PFS of 16.4 months vs 8.3 months for ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials ...

Most patients have mild skin reactions, while severe (grade 3-4) toxicities are found in a low proportion of patients (5.8% for the ipilimumab + nivolumab combination, even lower values for anti-PD-1 ...